AC
UTHR icon

Avestar Capital’s United Therapeutics UTHR Stock Holding History

Avestar Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15
Closed -$1K – 978
2019
Q1 		$1K Hold
15
– – ﹤0.01% 797
2018
Q4 		$1K Buy
15
+4
+36% +$464 ﹤0.01% 785
2018
Q3 		$1K Hold
11
– – ﹤0.01% 775
2018
Q2 		$1K Hold
11
– – ﹤0.01% 824
2018
Q1 		$0 Buy
+11
New +$1.4K ﹤0.01% 946

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Avestar Capital's UTHR Position: Q2 2019 in Review

Avestar Capital sold out of United Therapeutics (UTHR) in Q2 2019, closing a stake of 15 shares — an estimated $1K sold.

Avestar Capital first reported a position in UTHR in Q1 2018 and held it in 5 quarters. The position peaked at $1K in Q1 2019. 320 funds tracked by Wall St. Rank hold UTHR as of Q2 2019.

  • Avestar Capital reported no remaining United Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Avestar Capital sold 15 United Therapeutics shares in Q2 2019, an estimated $1K.
  • Avestar Capital first reported a position in United Therapeutics in Q1 2018 and held it in 5 quarters.
  • Avestar Capital's United Therapeutics position peaked at $1K in Q1 2019.
  • 320 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2019.

Based on Avestar Capital's 13F filing for Q2 2019, filed 6 Aug 2019.